Cybin (CYBN) Competitors

Cybin (NYSE:CYBN) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.

Which has better earnings and valuation, CYBN or AVXL?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$57.88M	-$4.38	-1.98
Anavex Life Sciences	N/A	N/A	-$43M	-$0.55	-14.85

Which has more volatility and risk, CYBN or AVXL?

Cybin has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Do analysts recommend CYBN or AVXL?

Cybin currently has a consensus price target of $86.00, indicating a potential upside of 891.93%. Anavex Life Sciences has a consensus price target of $44.00, indicating a potential upside of 438.56%. Given Cybin's higher probable upside, equities analysts clearly believe Cybin is more favorable than Anavex Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Anavex Life Sciences	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media refer more to CYBN or AVXL?

In the previous week, Anavex Life Sciences had 1 more articles in the media than Cybin. MarketBeat recorded 4 mentions for Anavex Life Sciences and 3 mentions for Cybin. Anavex Life Sciences' average media sentiment score of 1.53 beat Cybin's score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anavex Life Sciences	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do institutionals and insiders believe in CYBN or AVXL?

17.9% of Cybin shares are owned by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Is CYBN or AVXL more profitable?

Anavex Life Sciences' return on equity of -37.50% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-37.58%	-36.59%
Anavex Life Sciences	N/A	-37.50%	-34.08%

Does the MarketBeat Community favor CYBN or AVXL?

Anavex Life Sciences received 425 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 74.92% of users gave Anavex Life Sciences an outperform vote.

Company	Underperform	Outperform
Cybin	Outperform Votes 17 100.00%	Underperform Votes No Votes
Anavex Life Sciences	Outperform Votes 442 74.92%	Underperform Votes 148 25.08%

Summary

Anavex Life Sciences beats Cybin on 9 of the 14 factors compared between the two stocks.